Photo of Philip J. Saylor, MD

Philip J. Saylor, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-4000
Fax: (617) 726-8685


psaylor@mgh.harvard.edu

Photo of Philip J. Saylor, MD

Massachusetts General Hospital
Phone: (617) 724-4000
Fax: (617) 726-8685


psaylor@mgh.harvard.edu

Visualize Collaborations
Learn how these members are similar
Similar Members

HCC members that share similar concepts* with Philip J. Saylor, MD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

Philip J. Saylor, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Attending Physician, Internal Medicine (Hematology-Oncology), Massachusetts General Hospital

HCC PROGRAM AFFILIATION

Research Abstract

I am a clinical and translational investigator focused on prostate cancer treatment, molecular imaging, and survivorship. My clinical practice is focused on genitourinary oncology. I completed my oncology fellowship at the Dana Farber Cancer Institute/Massachusetts General Hospital in June 2010, training that featured a mentorship in clinical trial design and administration under Matthew R. Smith, M.D., Ph.D., Professor of Medicine. My research is carried out within MGH Cancer Center and the Dana Farber/Harvard Cancer Center.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Mei S, Zhang H, Hirz T, Jeffries NE, Xu Y, Baryawno N, Wu S, Wu CL, Patnaik A, Saylor PJ, Sykes DB, Dahl DM. Single-cell and spatial transcriptomics reveal a tumor-associated macrophage subpopulation that mediates prostate cancer progression and metastasis. Mol Cancer Res 2025. PubMed
  • Machacek ME, Wang H, Devins K, Sadow PM, Wu CL, Oliva E, Saylor PJ, Cornejo KM. A Proposal for Revised and Simplified Renal Pelvic Urothelial Carcinoma Staging Criteria: A Clinicopathologic Study of 141 Tumors. Am J Surg Pathol 2025; 49:113-120. PubMed
  • Coen JJ, Rodgers JP, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou J, Jani AB, Kucuk O, Souhami L, Pugh SL, Sandler HM, Shipley WU. Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer-Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial. Int J Radiat Oncol Biol Phys 2024. PubMed
  • Churchill TW, Smith MR, Michaelson MD, Lee RJ, Guseh JS, Wasfy MM, Meneely E, Olivier K, Baggish AL, Saylor PJ. Cardiac Structural Changes and Declining Cardiorespiratory Fitness During Androgen Deprivation Therapy for Prostate Cancer. 2024. PubMed
  • Mei S, Alchahin AM, Embaie BT, Gavriliuc IM, Verhoeven BM, Zhao T, Li X, Jeffries NE, Pepich A, Sarkar H, Olsen TK, Wickström M, Stenman J, Reina-Bedoya O, Kharchenko PV, Saylor PJ, Johnsen JI, Sykes DB, Kogner P, Baryawno N. Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signature. JCI Insight 2024. PubMed
  • Saylor PJ, Otani K, Balza R, Ukleja J, Pleskow H, Fisher R, Kusaka E, Otani YS, Badusi PO, Smith MR, Meneely E, Olivier K, Lowe AC, Toner M, Maheswaran S, Haber DA, Yeap BY, Lee RJ, Miyamoto DT. Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol 2024; 8:e2300230. PubMed
  • Mei S, Alchahin AM, Tsea I, Kfoury Y, Hirz T, Jeffries NE, Zhao T, Xu Y, Zhang H, Sarkar H, Wu S, Subtelny AO, Johnsen JI, Zhang Y, Salari K, Wu CL, Randolph MA, Scadden DT, Dahl DM, Shin J, Kharchenko PV, Saylor PJ, Sykes DB, Baryawno N. Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesions. Genome Med 2024; 16:1. PubMed
  • Saylor PJ, Kozin SV, Matsui A, Goldberg SI, Aoki S, Shigeta K, Mamessier E, Smith MR, Michaelson MD, Lee RJ, Duda DG. The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer. Radiother Oncol 2024; 192:110091. PubMed
  • Kamran SC, Zhou Y, Otani K, Drumm M, Otani Y, Wu S, Wu CL, Feldman AS, Wszolek M, Lee RJ, Saylor PJ, Lennerz J, Van Allen E, Willers H, Hong TS, Liu Y, Davicioni E, Gibb EA, Shipley WU, Mouw KW, Efstathiou JA, Miyamoto DT. Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer. Clin Cancer Res 2023. PubMed
  • Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G, Drumm M, Mari A, Thio E, Fleshner NE, Kulkarni GS, Jewett MAS, Bristow RG, Catton C, Berlin A, Sridhar SS, Schuckman A, Feldman AS, Wszolek M, Dahl DM, Lee RJ, Saylor PJ, Michaelson MD, Miyamoto DT, Zietman A, Shipley W, Chung P, Daneshmand S, Efstathiou JA. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023; 24:669-681. PubMed
  • Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, Subtelny AO, Zlatev DV, Wszolek MW, Salari K, Murray E, Chen F, Macosko EZ, Wu CL, Scadden DT, Dahl DM, Baryawno N, Saylor PJ, Kharchenko PV, Sykes DB. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun 2023; 14:663. PubMed
  • Alchahin AM, Mei S, Tsea I, Hirz T, Kfoury Y, Dahl D, Wu CL, Subtelny AO, Wu S, Scadden DT, Shin JH, Saylor PJ, Sykes DB, Kharchenko PV, Baryawno N. A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma. Nat Commun 2022; 13:5747. PubMed
  • Kfoury Y, Baryawno N, Severe N, Mei S, Gustafsson K, Hirz T, Brouse T, Scadden EW, Igolkina AA, Kokkaliaris K, Choi BD, Barkas N, Randolph MA, Shin JH, Saylor PJ, Scadden DT, Sykes DB, Kharchenko PV, . Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell 2021; 39:1464-1478.e8. PubMed
  • Massaad E, Saylor PJ, Hadzipasic M, Kiapour A, Oh K, Schwab JH, Schoenfeld AJ, Shankar GM, Shin JH. The effectiveness of systemic therapies after surgery for metastatic renal cell carcinoma to the spine: a propensity analysis controlling for sarcopenia, frailty, and nutrition. J Neurosurg Spine 2021. PubMed
  • Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, Balk SP, Einstein DJ. A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clin Cancer Res 2021. PubMed
  • Guarda FJ, Yu X, Shiraliyeva N, Haines MS, Bradbury M, Saylor PJ, Nachtigall LB. GnRH agonist-associated pituitary apoplexy: a case series and review of the literature. Pituitary 2021. PubMed
  • Shankar GM, Van Beaver LA, Choi BD, Hadzipasic M, Sivaganesan A, Karhade AV, Ferrone ML, Harris MB, Schoenfeld AJ, Sadow PM, Oh K, Schwab JH, Saylor PJ, Shin JH. Survival After Surgery for Renal Cell Carcinoma Metastatic to the Spine: Impact of Modern Systemic Therapies on Outcomes. Neurosurgery 2020. PubMed
  • Saylor PJ, Rumble RB, Michalski JM. Bone Health and Bone-Targeted Therapies for Prostate Cancer: American Society of Clinical Oncology Endorsement Summary of a Cancer Care Ontario Guideline. JCO Oncol Pract 2020. PubMed
  • Saylor PJ, Rumble RB, Tagawa S, Eastham JA, Finelli A, Reddy PS, Kungel TM, Nissenberg MG, Michalski JM. Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. J Clin Oncol 2020. PubMed
  • Amorim BJ, Prabhu V, Marco SS, Gervais D, Palmer WE, Heidari P, Vangel M, Saylor PJ, Catalano OA. Performance of F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2019. PubMed
  • Karhade AV, Thio QCBS, Ogink PT, Bono CM, Ferrone ML, Oh KS, Saylor PJ, Schoenfeld AJ, Shin JH, Harris MB, Schwab JH. Predicting 90-Day and 1-Year Mortality in Spinal Metastatic Disease: Development and Internal Validation. Neurosurgery 2019. PubMed
  • Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, Souhami L, Rodgers JP, Sandler HM, Shipley WU. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol 2019; 37:44-51. PubMed
  • Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017. PubMed
  • Saylor PJ, Lee RJ, Arora KS, Deshpande V, Hu R, Olivier K, Meneely E, Rivera MN, Ting DT, Wu CL, Miyamoto DT. Branched chain RNA in situ hybridization for androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castration-sensitive prostate cancer. Clin Cancer Res 2016. PubMed
  • Singh H, Liu Y, Xiao X, Lin L, Kim J, Van Hummelen P, Wu CL, Bass AJ, Saylor PJ. Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations. 2016. PubMed
  • Ryan CJ, Saylor PJ, Everly JJ, Sartor O. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. Oncologist 2014; 19:1012-8. PubMed
  • Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 2014; 32:1143-50. PubMed
  • Saylor PJ, Smith MR, O'Malley AJ, Keating NL. Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer. Eur Urol 2014. PubMed
  • Saylor PJ. Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer. Asian J. Androl. 2014. PubMed
  • Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 2013. PubMed
  • Saylor PJ. Prostate cancer: The androgen receptor remains front and centre. Nat Rev Clin Oncol 2013; 10:126-8. PubMed
  • Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 2013; 63:309-20. PubMed
  • Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. J Nucl Med 2012; 53:1670-5. PubMed
  • Saylor PJ, Karoly ED, Smith MR. Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res 2012; 18:3677-85. PubMed
  • Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone 2011; 48:88-95. PubMed
  • Lee RJ, Saylor PJ, Smith MR. Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer 2010; 8:29-36. PubMed
  • Saylor PJ. Re: Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy. Editorial comment. J Urol 2010; 184:923; author reply 924. PubMed
  • Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol 2010; 183:2200-5. PubMed
  • Saylor PJ, Fogerty AE. Prostate-cancer-associated hypercoagulability: do we need to worry about androgen deprivation? Lancet Oncol 2010; 11:406-7. PubMed
  • Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw 2010; 8:211-23. PubMed
  • Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med 2009; 24 Suppl 2:S389-94. PubMed
  • Saylor PJ, Smith MR. Prostate cancer: How can we improve the health of men who receive ADT? Nat Rev Urol 2009; 6:529-31. PubMed
  • Saylor PJ, Michaelson MD. New treatments for renal cell carcinoma: targeted therapies. J Natl Compr Canc Netw 2009; 7:645-56. PubMed
  • Saylor PJ,Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009; 181:1998-2006; discussion 2007-8. PubMed
  • Saylor PJ, Reid TR. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol 2007; 25:3544-6. PubMed
Hide
Visualize Collaborations
Learn how these members are similar
Similar Members

HCC members that share similar concepts* with Philip J. Saylor, MD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members